A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis.

Hisashi TanakaShigeru TanzawaToshihiro MisumiTomonori MakiguchiMegumi InabaTakeshi HondaJunya NakamuraKoji InoueTakayuki KishikawaMasanao NakashimaKeiichi FujiwaraTadashi KohyamaHiroo IshidaShoichi KuyamaNaoki MiyazawaTomomi NakamuraHiroshi MiyawakiNaohiro OdaNobuhisa IshikawaRyotaro MorinagaKei KusakaNobukazu FujimotoYasushi FukudaMasayuki YasugiTakeshi TsudaSunao UshijimaKazuhiko ShibataTakuo ShibayamaAkihiro BesshoKyoichi KairaKenshiro ShiraishiNoriyuki MatsutaniNobuhiko Seki

Published in: Therapeutic advances in medical oncology (2022)

Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127.

Keyphrases

locally advanced
phase ii study
advanced non small cell lung cancer
rectal cancer
clinical trial
squamous cell carcinoma
radiation therapy
epidermal growth factor receptor
open label
spinal cord
early stage
study protocol
tyrosine kinase